A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.

Sophie Leboulleux Christine Do Cao Slimane Zerdoud Marie Attard Claire Bournaud Ludovic Lacroix Danielle Benisvy David Taïeb Stephane Bardet Marie Terroir Nadege Anizan Emilie Bouvier-Morel Livia Lamartina Georges Lion Sarah Bétrian Christophe Sajous Aurelie Schiazza Marie-Eve Garcia Renaud Ciappuccini Martin Schlumberger Abir Al Ghuzlan Yann Godbert Isabelle Borget

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Dabrafenib-trametinib is effective in BRAFp.V600E mutated DTC patients for restoring 131I uptake with partial response observed 6 months after 131I administration in 38% of the patients.

Keyphrases

phase ii
end stage renal disease
clinical trial
newly diagnosed
peritoneal dialysis
squamous cell carcinoma
prognostic factors
small cell lung cancer
computed tomography
randomized controlled trial
open label
metastatic colorectal cancer
wild type